So targeting CD39, CD73, and adenosine receptors in the presence of immune checkpoint therapy (anti-PDL1/PD1; ANTI CTLA-4) can prove to be a novel immunotherapeutic strategy against immune-resistant cancer cells. This evidence concerns the gene ENTPD1 and cancer.